 |
Broxuridine |
|---|---|
| Trade Name | Broxine/Neomark |
| Orphan Indication | Radiation sensitizer in the treatment of primary brain tumors |
| USA Market Approval | USA |
| USA Designation Date | 1995-09-18 00:00:00 |
| Sponsor | NeoPharm, Inc.;225 East Deerpath, Suite 250;Lake Forest, Illinois, 60045 |
